

Rob Ter Heine

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8227615/publications.pdf>

Version: 2024-02-01

72
papers

982
citations

471061

17
h-index

552369

26
g-index

74
all docs

74
docs citations

74
times ranked

1388
citing authors

#	ARTICLE	IF	CITATIONS
1	Proposal for individualized dosing of eculizumab in atypical haemolytic uraemic syndrome: patient friendly and cost-effective. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 362-371.	0.4	3
2	A meta-analysis of protein binding of flucloxacillin in healthy volunteers and hospitalized patients. <i>Clinical Microbiology and Infection</i> , 2022, 28, 446.e1-446.e7.	2.8	8
3	Hyperhydration with cisplatin does not influence pemetrexed exposure. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 871-876.	1.1	2
4	The effect of chemotherapy on the exposure–response relation of abiraterone in metastatic castration-resistant prostate cancer. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1170-1178.	1.1	5
5	Pyronaridine–artesunate or dihydroartemisinin–piperaquine combined with single low-dose primaquine to prevent <i>Plasmodium falciparum</i> malaria transmission in Ouasséboougou, Mali: a four-arm, single-blind, phase 2/3, randomised trial. <i>Lancet Microbe</i> , The, 2022, 3, e41-e51.	3.4	12
6	Variation in vancomycin dosing and therapeutic drug monitoring practices in neonatal intensive care units. <i>International Journal of Clinical Pharmacy</i> , 2022, 44, 564-569.	1.0	3
7	The Pharmacoeconomic Benefits of Pemetrexed Dose Individualization in Patients With Lung Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 1103-1110.	2.3	2
8	Posaconazole bioavailability of the solid oral tablet is reduced during severe intestinal mucositis. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1003-1009.	2.8	8
9	Efficacy of BCG Vaccination Against Respiratory Tract Infections in Older Adults During the Coronavirus Disease 2019 Pandemic. <i>Clinical Infectious Diseases</i> , 2022, 75, e938-e946.	2.9	44
10	Lactate infusion as therapeutical intervention: a scoping review. <i>European Journal of Pediatrics</i> , 2022, , 1.	1.3	8
11	Single low-dose tafenoquine combined with dihydroartemisinin–piperaquine to reduce <i>Plasmodium falciparum</i> transmission in Ouelesseboougou, Mali: a phase 2, single-blind, randomised clinical trial. <i>Lancet Microbe</i> , The, 2022, 3, e336-e347.	3.4	11
12	Pharmacokinetically guided dosing to improve the efficacy of brigatinib in non-small cell lung cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3920-3921.	1.1	0
13	An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients. <i>Clinical Pharmacokinetics</i> , 2022, 61, 907-918.	1.6	10
14	Pharmacokinetic evaluation of twice-a-week micafungin for prophylaxis of invasive fungal disease in children with acute lymphoblastic leukaemia: a prospective observational cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 699-703.	1.3	3
15	Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer. <i>Drugs</i> , 2022, 82, 15-32.	4.9	3
16	Model-Informed Precision Dosing of Everolimus: External Validation in Adult Renal Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2021, 60, 191-203.	1.6	7
17	The bioavailability and maturing clearance of doxapram in preterm infants. <i>Pediatric Research</i> , 2021, 89, 1268-1277.	1.1	7
18	Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 727-733.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis. <i>Clinical Pharmacokinetics</i> , 2021, 60, 649-654.	1.6	7
20	A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis. <i>Clinical Pharmacokinetics</i> , 2021, 60, 943-953.	1.6	5
21	The potential of individualized dosing of ravulizumab to improve patientâ€friendliness of paroxysmal nocturnal haemoglobinuria treatment at reduced costs. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3359-3363.	1.1	6
22	Chloroquine for treatment of COVID-19 results in subtherapeutic exposure and prolonged QTc intervals. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106293.	1.1	1
23	Toxicity of pemetrexed during renal impairment explainedâ€”Implications for safe treatment. <i>International Journal of Cancer</i> , 2021, 149, 1576-1584.	2.3	9
24	High unbound flucloxacillin fraction in critically ill patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3220-3228.	1.3	9
25	Point-of-Care Detection of Nonadherence to Antiretroviral Treatment for HIV-1 in Resource-Limited Settings Using Drug Level Testing for Efavirenz, Lopinavir, and Dolutegravir: A Validation and Pharmacokinetic Simulation Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 1072-1078.	0.9	2
26	Nicotinamide Riboside Improves Ataxia Scores and Immunoglobulin Levels in Ataxia Telangiectasia. <i>Movement Disorders</i> , 2021, 36, 2951-2957.	2.2	18
27	Pharmacokineticallyâ€guided dosing to improve the efficacy of brigatinib in nonâ€small cell lung cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	1.1	2
28	Model-based assessment of the safety of community interventions with primaquine in sub-Saharan Africa. <i>Parasites and Vectors</i> , 2021, 14, 524.	1.0	1
29	Mechanisms, Management and Prevention of Pemetrexed-Related Toxicity. <i>Drug Safety</i> , 2021, 44, 1271-1281.	1.4	10
30	Highly sensitive quantification of pemetrexed in human plasma by means of UPLCâ€MS/MS to support microdosing studies. <i>Biomedical Chromatography</i> , 2021, , e5277.	0.8	4
31	Effects of dalteparin on antiâ€Xa activities cannot be predicted in critically ill COVIDâ€19 patients. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	1.1	4
32	A limited sampling schedule to estimate individual pharmacokinetics of pemetrexed in patients with varying renal functions. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 231-235.	1.1	3
33	Validation of an analytical method using HPLCâ€MS/MS to quantify osimertinib in human plasma and supplementary stability results. <i>Biomedical Chromatography</i> , 2020, 34, e4771.	0.8	16
34	Simple and Rapid Quantification of the Multi-Enzyme Targeting Antifolate Pemetrexed in Human Plasma. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 146-150.	1.0	4
35	Low Bioavailability of Oral Tacrolimus Suspension in Pediatric Kidney Transplant Patients. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1483-1485.	1.6	1
36	Suboptimal Dosing of Fluconazole in Critically Ill Patients: Time To Rethink Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	22

#	ARTICLE	IF	CITATIONS
37	Authorâ€™s Reply to Liu et al.: â€œPharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumabâ€. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1645-1646.	1.6	0
38	Prospective validation of a modelâ€informed precision dosing tool for vancomycin in intensive care patients. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2497-2506.	1.1	25
39	Personalised antimicrobial dosing: standing on the shoulders of giants. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106062.	1.1	6
40	Two Randomized Controlled Trials of Bacillus Calmette-GuÃ©rin Vaccination to reduce absenteeism among health care workers and hospital admission by elderly persons during the COVID-19 pandemic: A structured summary of the study protocols for two randomised controlled trials. <i>Trials</i> , 2020, 21, 481.	0.7	38
41	Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin-based HIPEC: results of the GUTOX study. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 141-150.	1.1	3
42	Drug level testing as a strategy to determine eligibility for drug resistance testing after failure of ART: a retrospective analysis of South African adult patients on secondâ€line ART. <i>Journal of the International AIDS Society</i> , 2020, 23, e25501.	1.2	12
43	Higher Dosage of Ciprofloxacin Necessary in Critically Ill Patients: A New Dosing Algorithm Based on Renal Function and Pathogen Susceptibility. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 770-774.	2.3	10
44	Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient. <i>Frontiers in Immunology</i> , 2020, 11, 612706.	2.2	9
45	A New Framework to Implement Model-Informed Dosing in Clinical Guidelines: Piperacillin and Amikacin as Proof of Concept. <i>Frontiers in Pharmacology</i> , 2020, 11, 592204.	1.6	7
46	Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps. <i>Clinical Pharmacokinetics</i> , 2019, 58, 309-323.	1.6	41
47	Is vancomycin clearance really correlated with hemoglobin? Arguments that itâ€™s not. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1617-1618.	0.8	0
48	Nonlinear protein binding of phenytoin in clinical practice: Development and validation of a mechanistic prediction model. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2360-2368.	1.1	9
49	Personalized Tuberculosis Treatment Through Model-Informed Dosing of Rifampicin. <i>Clinical Pharmacokinetics</i> , 2019, 58, 815-826.	1.6	25
50	The effect of neutropenia on the clinical pharmacokinetics of vancomycin in adults. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 921-928.	0.8	22
51	Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1348-1356.	1.3	8
52	Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab. <i>Clinical Pharmacokinetics</i> , 2019, 58, 859-874.	1.6	82
53	Neurodevelopmental and behavioral consequences of perinatal exposure to the HIV drug efavirenz in a rodent model. <i>Translational Psychiatry</i> , 2019, 9, 84.	2.4	9
54	Population pharmacokinetic modelling of total and unbound flucloxacillin in non-critically ill patients to devise a rational continuous dosing regimen. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 310-317.	1.1	20

#	ARTICLE	IF	CITATIONS
55	Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 978-985.	1.3	23
56	The potential impact of hematocrit correction on evaluation of tacrolimus target exposure in pediatric kidney transplant patients. <i>Pediatric Nephrology</i> , 2019, 34, 507-515.	0.9	13
57	Bone-Targeting Radiopharmaceuticals as Monotherapy or Combined With Chemotherapy in Patients With Castration-Resistant Prostate Cancer Metastatic to Bone. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e281-e292.	0.9	9
58	Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis: a clinical pharmacological perspective on a surgical procedure. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 47-58.	1.1	19
59	Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome. <i>Pediatric Nephrology</i> , 2019, 34, 389-403.	0.9	50
60	A clinically relevant decrease in abiraterone exposure associated with carbamazepine use in a patient with castration-resistant metastatic prostate cancer. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1064-1067.	1.1	7
61	Pharmacokinetics of Anidulafungin in Obese and Normal-Weight Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	28
62	A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400Åmg in Pregnant Women. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1421-1433.	1.6	6
63	Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2018, 57, 229-242.	1.6	21
64	Model-Informed Precision Dosing at the Bedside: Scientific Challenges and Opportunities. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 785-787.	1.3	84
65	Simulation-based suggestions to improve ibuprofen dosing for patent ductus arteriosus in preterm newborns. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1585-1591.	0.8	14
66	Caspofungin dosage adjustments are not required for patients with Child-Pugh B or C cirrhosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2493-2496.	1.3	14
67	Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1197-1206.	1.6	27
68	Boosting axitinib exposure with a CYP3A4 inhibitor, making axitinib treatment personal. <i>Acta Oncologica</i> , 2017, 56, 1238-1240.	0.8	16
69	Cytotoxic Effects of the Therapeutic Radionuclide Rhenium-188 Combined with Taxanes in Human Prostate Carcinoma Cell Lines. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2017, 32, 16-23.	0.7	6
70	Age, Weight, and <i>CYP2D6</i> Genotype Are Major Determinants of Primaquine Pharmacokinetics in African Children. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	37
71	Cost of illness of metastatic prostate cancer: a perspective of costs for new treatment options in The Netherlands. <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 575-581.	0.6	1
72	A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1447-1456.	1.6	17